Combined loss of tumor suppressors (TSPs), PTEN, TP53, and RB1, is highly associated with small cell carcinoma of prostate phenotype. Recent genomic studies of human tumors as well as analyses in mouse genetic models have revealed a unique role for these TSPs in dictating epithelial lineage plasticity-a phenomenon that plays a critical role in the development of aggressive variant prostate cancer (PCa) and associated androgen therapy resistance. Here, we summarize recently published key observations on this topic and hypothesize a possible mechanism by which concurrent loss of TSPs could potentially regulate the PCa disease phenotype.
Frontiers in oncology. 2018 Mar 15*** epublish ***
Rama Soundararajan, Ana M Aparicio, Christopher J Logothetis, Sendurai A Mani, Sankar N Maity
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.